Houston Methodist part of national consortium to develop vaccine against herpesviruses

Houston Methodist researchers will be part of a national consortium funded by an up to $49 million award from the U.S. Government’s Advanced Research Projects Agency for Health (ARPA-H) to develop a vaccine against two of the most common and destructive strains of herpesviruses that latently infect a majority of Americans and can lead to acute infections, multiple forms of cancer, autoimmune disease and birth defects.

People with Long COVID Have Distinct Hormonal and Immune Differences From Those Without This Condition

Research conducted at Mount Sinai and Yale confirms long COVID is a biological disease by showing blood biomarkers that can predict who has it